Transformation of cutaneous gamma/delta T-cell lymphoma following 15 years of indolent behavior.
Subcutaneous gamma/delta (gamma/delta) T-cell lymphoma is a rare lymphoma, characterized by its unique immunophenotype and clinical course. It has been shown to behave more aggressively than its counterpart bearing the alpha/beta receptor and has recently been removed from the subcutaneous panniculitis-like T-cell lymphoma category for this very reason. We present a case of a patient with a 15-year running diagnosis of panniculitis. Following these years of indolent behavior, the disease began an aggressive clinical course and she was diagnosed with gamma/delta T-cell lymphoma. Molecular analysis identified a T-cell clone, which through retrospective analysis, was also shown to be present in the patient's original biopsy material. We present this case as a rare example of initial indolent behavior in a lymphoma typically considered very aggressive.
Hosler
Gregory A
GA
Department of Dermatology, Johns Hopkins University, Baltimore, MD, USA. gregory.hosler@propathlab.com
Liégeois
Nanette
N
Anhalt
Grant J
GJ
Moresi
J Margaret
JM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D002999:Clone Cells; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D015434:Panniculitis / Q000473:pathology*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000378:metabolism*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D013601:T-Lymphocytes / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D016692:Receptors, Antigen, T-Cell, gamma-delta; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D007069:Ifosfamide; D011241:Prednisone